Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chubb
Cerilliant
Express Scripts
McKesson
Dow
Mallinckrodt
Harvard Business School
QuintilesIMS

Generated: June 20, 2018

DrugPatentWatch Database Preview

VISIPAQUE 270 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Visipaque 270, and what generic alternatives are available?

Visipaque 270 is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in VISIPAQUE 270 is iodixanol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iodixanol profile page.
Drug patent expirations by year for VISIPAQUE 270
Pharmacology for VISIPAQUE 270
Synonyms for VISIPAQUE 270
1,3-Benzenedicarboxamide, 5,5'-((2-hydroxy-1,3-propanediyl)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
1,3-Benzenedicarboxamide, 5,5'-[(2-hydroxy-1,3- propanediyl)bis(acetylimino)]bis[N,N'-bis(2,3- dihydroxypropyl)-2,4,6-triiodo-
2-5410-3A
2-541O-3A
339I112
5-(Acetyl-(3-(acetyl-(3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodophenyl)amino)-2- hydroxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide; 5,5'-((2-hydroxytrimethylene)bis(acetylimino
5-[[3-[[3,5-bis[2,3-bis(oxidanyl)propylcarbamoyl]-2,4,6-tris(iodanyl)phenyl]-ethanoyl-amino]-2-oxidanyl-propyl]-ethanoyl-amino]-N1,N3-bis[2,3-bis(oxidanyl)propyl]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
5-[acetyl-[3-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodo-anilino]-2-hydroxy-propyl]amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide
5-[acetyl-[3-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[acetyl-[3-[N-acetyl-3,5-bis[(2,3-dihydroxypropylamino)-oxomethyl]-2,4,6-triiodoanilino]-2-hydroxypropyl]amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-{N-[3-(N-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5,5'-((2-Hydroxytrimethylene)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
5,5'-[(2-hydroxypropane-1,3-diyl)bis(acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide]
92339-11-2
A844203
AB00513936
AB00513936_02
AC-7610
AC1L1GKH
Acupaque
AKOS015895607
AM039197
AN-8826
BPBio1_000919
BRD-A08660406-001-01-8
BSPBio_000835
C-23647
CAS-92339-11-2
CC-29560
CCG-213207
CCRIS 7567
CHEBI:31705
CHEMBL1200507
CTK8G0329
D01474
D0Y4YG
DB01249
DR003748
DSSTox_CID_25523
DSSTox_GSID_45523
DSSTox_RID_80929
DTXSID2045523
DU-6807
EC 618-837-0
FT-0627254
FT-0645028
GP8799
HMS1570J17
HMS2097J17
HSDB 8076
HW8W27HTXX
Indixanol
iodixanol
Iodixanol (JAN/USP/INN)
Iodixanol [USAN:BAN:INN]
Iodixanol [USAN:USP:INN:BAN]
Iodixanolum
Iodixanolum [Latin]
LS-29753
NBQNWMBBSKPBAY-UHFFFAOYSA-N
NCGC00016958-01
NCGC00179408-01
NCGC00179408-03
NSC-760069
NSC760069
OptiPrep
OptiPrep(TM) Density Gradient Medium, used for cell and subcellular organelle isolation
Pharmakon1600-01503835
Prestwick0_000848
Prestwick1_000848
Prestwick2_000848
Prestwick3_000848
SCHEMBL21546
SPBio_002756
SR-01000872678
SR-01000872678-2
Tox21_110711
Tox21_110711_1
UNII-HW8W27HTXX
Visipaque
Visipaque (TN)
Visipaque 320

US Patents and Regulatory Information for VISIPAQUE 270

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020351-001 Mar 22, 1996 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020808-001 Aug 29, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for VISIPAQUE 270

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020351-001 Mar 22, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020808-001 Aug 29, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020808-001 Aug 29, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020351-001 Mar 22, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Chinese Patent Office
Accenture
Fuji
Federal Trade Commission
Argus Health
Dow
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.